ALK and non-small cell lung carcinoma: In a multivariate analysis including the parameters antibiotic treatment status, sex, immune-checkpoint inhibitor, EGFR mutation status, ALK translocation status, number of prior therapy lines, PD-L1 expression status, and immune-related adverse events, the antibiotic treatment status was the only parameter statistically significantly associated with PFS (HR=5.34, p=0.028) and OS (HR=14.81, p=0.026) in our non-squamous NSCLC cohort receiving ICB (Table 2).